RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Early trial probes new drug cocktail for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study is testing the safety and best dose of a three-drug combination for patients with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. The drugs—venetoclax, lenalidomide, and rituximab hyaluronidase—work together to h…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Scientists test new drug duo in fight against stubborn lymphoma
Disease control OngoingThis early-stage study is testing the safety and best dose of a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has come back or stopped responding to other treatments. The goal is to see if this drug pair can help control the cancer and is sa…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Early trial aims to tame Tough-to-Treat lymphomas with drug cocktail
Disease control OngoingThis early-stage study is testing a combination of three drugs—alisertib, bortezomib, and rituximab—in patients whose mantle cell or low-grade B-cell lymphoma has returned or stopped responding to other treatments. The main goal is to find the safest and most effective doses of t…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New immune therapy combo targets stubborn lymphoma
Disease control OngoingThis study is testing whether a combination of two drugs, epcoritamab and lenalidomide, can help control a specific type of aggressive lymphoma that has come back or hasn't responded to other treatments. The trial is for adults whose cancer is linked to a weakened immune system a…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New drug combo tested to fight tough blood cancers
Disease control OngoingThis study is testing if adding a new drug called selinexor to the standard chemotherapy regimen (RCHOP) is safe and more effective for treating B-cell non-Hodgkin's lymphoma. It will first find the safest dose of the combination, then see how well it works for newly diagnosed pa…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New immune attack on tough cancers: can a combo drug beat the odds?
Disease control OngoingThis study is testing whether adding a new immunotherapy drug (varlilumab) to an existing one (nivolumab) works better than nivolumab alone for patients with aggressive B-cell lymphomas that have come back or stopped responding to standard treatments. The goal is to see if the tw…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New 'Living Drug' trial offers hope for patients with aggressive lymphoma
Disease control OngoingThis study is testing a new type of personalized cell therapy for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better tar…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC